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INTRODUCTION
Patients with glioblastoma (GBM) treated with a standard radiation therapy (RT) dose of 60 Gy, typically progress in the high dose region. [1] [2] [3] Although the addition of concurrent and adjuvant temozolomide (TMZ) has improved over all survival, a majority of tumors continue to progress locally. [4] [5] One possible explanation for this lack of local control is that the current standard dose of 60 Gy is insufficient. Recent advances in RT delivery, such as intensity modulated radiation (IMRT), 6 might permit us to safely escalate RT doses by limiting the RT dose to normal tissues 7 which, when combined with effective chemotherapy, may improve outcome.
An important obstacle to the effectiveness of dose escalated RT is the inability to precisely target the tumor. Evidence now suggests that amino acid positron emission tomography (PET) using 11 C methionine (MET-PET) may identify glioma beyond the region identified by conventional magnetic resonance imaging (MRI). [8] [9] [10] [11] However, no large prospective studies have yet correlated MET-PET uptake with patterns of failure after treatment, although such information could be very useful in optimizing the regions requiring high-dose RT for primary GBM. 12 We hypothesized that the use of IMRT would permit us to escalate the dose of RT with concurrent TMZ substantially above the 60 Gy currently used.
Thus, the primary objective of this study was to determine the maximum tolerated dose (MTD) of IMRT delivered over 6 weeks with concurrent TMZ in primary GBM, as well as to make a preliminary estimate of the overall survival (OS) and the progression free survival (PFS). A second important goal of this study was to assess the patterns of failure in patients who had prospectively undergone MET-PET imaging. We hypothesized that a subset of patients might progress in MET-PET avid regions outside the standard target defined by T1 gadolinum-enhanced MRI. In such cases, MET-PET might improve standard targeting by identifying areas at highest risk of recurrence in future studies. MET-PET was obtained on a Siemens ECAT EXACT HR+ whole body tomography (axial resolution 4.1 mm full width at half maximum in the center of the field of view. 13 Following intravenous injection of approximately 740 MBq of 11 C MET in a dynamic acquisition, emission scans were obtained in a threedimensional mode. Summed image data obtained between 10 and 30 minutes post injection were utilized for further analysis. PET uptake was defined by automatic segmentation using a threshold of 1.5 times mean activity and normalized to the mean activity of the normal brain, defined as the cerebellum as previously described. 14 
METHODS AND MATERIALS

Patient eligibility
Image registration
A treatment planning computed tomography (CT) scan was obtained with the patient immobilized in an individualized thermoplastic mask. . Image registration of research scans was performed using functional imaging analysis tools (FIAT), a software package developed at the University of Michigan. 15 Registration of the accumulated RT dose plan was accomplished by applying the same transformation. These methods are able to detect discrepancies in registration with a magnitude of 1 voxel or approximately 2-3 mm.
TITE-CRM RT dose allocation
Individual RT dose levels were allocated according to the TITE-CRM algorithm. 16 Per protocol a dose limiting toxicity was defined as any grade 3 or 4 irreversible CNS toxicity, non-hematologic, non-CNS grade 4 toxicity or any grade 5 toxicity. For each patient, the probability of dose-limiting toxicity (DLT) was estimated based on the expected risk, as well as the incidence of DLT in patients already treated, weighted by the amount of time patients had been followed. At the time of study enrollment, each patient was assigned RT dose with estimated probability of DLT closest but less than the target rate of 25%. RT dose escalation was restricted to one level between sequential patients. Prior to assigning patients to the next higher RT dose level, at least one patient treated at the previous level completed three months of observation without any DLT.
RT Volumes
Gross tumor volumes (GTVs) were defined as the residual gross tumor or resection cavity, based on the contrast enhancing T1-weighted MRI. GTVs were expanded within the skull uniformly by 1.5 cm to form the clinical target volume (CTV). CTV and GTV were expanded uniformly by 0.5 cm to generate planning target volumes, (PTV1 and PTV2, respectively). IMRT plans were generated to deliver 60 Gy in 30 fractions to PTV1 and a simultaneous higher dose (range, 66-81 Gy) to the smaller target, PTV2. T2/FLAIR signal abnormality was not targeted. The maximum dose limits to normal tissue organs at risk were defined as 60 bioGy to the optic nerves and chiasm, and brainstem was limited to 65 bioGy using alpha/beta ratio of 2.5. 
Chemotherapy
Toxicity
Chemotherapy and radiation toxicities were graded using the Common Toxicity Criteria (CTC) version 3.0. 17 Acute toxicity was assessed during the first 90 days following RT. Late toxicity was assessed every 3 months during the first year and every 6 months thereafter. All patients were monitored for late CNS toxicity until death. Additional imaging studies including MR Spectroscopy,MET-PET and if possible stereotactic biopsies were obtained at time of suspected tumor progression to differentiate it from radiation necrosis.
Response Criteria
Conventional MRI was obtained at 1 month, and every 2-3 months thereafter. Response was defined using standard Macdonald criteria. 18 As published data regarding pseudo-progression became available, a finding of worsening enhancement noted within 3 months of treatment completion was followed closely for progression versus pseudo-progression. Second line therapy was given at the physician's discretion following progression. A pattern of failure was determined by registering the MRI at progression with the delivered RT dose distribution as previously described. 19 The location of failure was classified according to the proportion of the volume of the rVOI contained within the 95% high dose prescription isodose surface: central (>95%), in field (>80-95%), marginal (20-80%), or distant (<20%). MET PET images were co-registered with the baseline MR post-gadolinium T1 as well as recurrence MRI.
Statistical analysis
The primary endpoint was to evaluate the rate of acute and late treatmentrelated toxicities. A standard two-parameter logistic regression model was used at the end of the trial to obtain estimated probabilities of toxicity by dose.
Secondary endpoints included PFS and OS. Kaplan-Meier estimates of median PFS and OS functions were determined with 95% confidence intervals. PFS was measured from the date of resection to progression, death, or last follow-up.
Univariate proportional hazards regression models were used to assess the relation of dose and other clinical covariates to PFS and/or OS. Fisher's exact test was used to test for an association between coverage of PET GTV and subsequent non-central failure.
RESULTS
Patient characteristics
Between November 2003 and August 2007, 42 consecutive patients were enrolled. Three patients did not participate due to a subsequent determination of ineligibility (delay in RT > 5 wks in 2 patients) or withdrawn consent (1 patient). One patient was non-evaluable for DLT per protocol due to clinical deterioration following the initial five RT fractions. MR scan showed tumor progression; all therapies were halted and the patient was transferred to hospice. This patient was included for survival analysis. The remaining thirty-eight patients were analyzed for long-term toxicity, with a median follow-up of 54 months (range: 42-62) for patients who remain alive. Patient characteristics are listed in Table 1 .
The median patient age was 56 years (range: 23-75).
Toxicities
Acute toxicities were primarily hematologic toxicities and infections (Table   2 ). Three grade 5 acute toxicities due to TMZ were observed: (1 patient) sepsis, 75 Gy; (1 patient) prolonged and severe thrombocytopenia with pancytopenia, 75Gy; (1 patient) aplastic anemia assigned to 81 Gy. Aplastic anemia is a rare but reported adverse event with TMZ. 21 Neither of the patients was receiving trimethoprim-sulfamethoxazole or other drugs known to suppress blood counts. Fifteen patients underwent a second resection due to either new imaging findings to confirm tumor progression (9) or progressive clinical symptoms (6).
Pathology review showed recurrent GBM in 5 patients; RT dose delivered was 66, 72(2 patients), 75, and 78 Gy. Multifocal radiation necrosis with no evidence of residual glioma was noted in 2 patients treated to 78 Gy. Both recurrent GBM and radiation changes with areas of vascular hyalinization, gliosis, and coagulative necrosis were noted in 8 patients RT dose was delivered to72 Gy (3 patients), 78 Gy (2 patients), and 81 Gy (3 patients).
Survival
Median PFS was 9.0 months (95% CI: 6.0, 11.7) and median OS was 20. 
CNS toxicity was not observed with RT doses at or below 75 Gy with concurrent TMZ. Furthermore, we found that patients tended to progress in regions of inadequate coverage of the tumor defined by MET-PET uptake. This suggests that MET-PET is useful in determining tumor extent, and encourages further exploration of using functional imaging to define target volumes as a method of decreasing recurrence in primary GBM.
Prior RT dose escalation trials using RT alone or less effective chemotherapy, including UM 90 Gy dose escalation study 22 , RTOG phase III stereotactic radio-surgery boost trial, 23 RTOG phase I 3D dose escalation study, 24 and BTCG randomized phase III interstitial brachytherapy boost trial, 25 all failed to demonstrate improved survival. Most likely, these studies failed because the RT doses required for tumor cell kill exceeded normal brain tolerance limits. The EORTC/NCIC phase III trial of concurrent TMZ with standard 60 Gy RT followed by adjuvant TMZ confirmed modest gains in long-term outcome. 5 The combination of highly conformal, dose escalated RT and effective chemotherapy that radiosensitizes may improve the effectiveness of radiation at dose levels tolerable to the normal brain.
A key finding of our study is that MET-PET appears to define regions of active tumor not apparent using T1 gadolinium-enhanced MRI. Ki-67 staining, proliferating cell nuclear antigen expression, and microvessel density. [27] [28] [29] These studies suggest that MET-PET may improve delineation of tumor extent in gliomas compared to conventional MRI imaging.
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These findings are consistent with our observation that inadequate coverage of the region of MET-PET uptake, which can occur when using only standard targeting of the T1-gadolinium enhanced region was associated with area of eventual recurrence.
Our median OS compares favorably with other recently reported GBM trials. However, our study was conducted in an era prior to the routine use of salvage bevacizumab. A number of patients underwent stereotactic biopsies, and a number of patients older than seventy years of age were included. MGMT analysis was performed in a limited number of patients.(26%) MGMT analysis is currently underway in the remaining patients. A recent phase II study examining the use of a novel anti-angiogenic agent, bevacizumab in combination with standard TMZ and RT, reported a median OS of 19.6 months, a significant improvement over the previous EORTC/NCIC data. 30 In comparison, recently RT/TMZ treated groups have also shown a median OS of 18-20 months in patients treated with either an additional novel chemotherapeutic or received salvage bevacizumab at recurrence. [30] [31] Although this is a small prospective single institutional study, this is the first study to confirm the safety and tolerability of delivering higher radiation doses with concurrent TMZ delivered in six weeks. We found that 75 Gy in 30 fractions was the maximum radiation dose delivered with concurrent TMZ without a substantial risk of radiation necrosis. It is possible that still higher doses could showed that the addition of bevacizumab combined with a highly hypofractionated course of re-irradiation over 5 treatments in recurrent gliomas surprisingly reported no cases of radiation necrosis. 32 The addition of bevacizumab to chemoradiation may increase the therapeutic ratio through possible anti-tumor effects as well as by allowing the safe escalation of RT by reducing the toxicity associated with radiation necrosis. Thus, it would be reasonable to investigate adding bevacizumab to the combination of TMZ and dose intensified radiation, with the target volume defined using MET-PET. This is a study we are now initiating. This strategy may be of particularly interest in patients predicted to have poor outcome, i.e non-methylated MGMT tumors. 
